U.O. di Ematologia
- Address
- lock Available on a paid plan
U.O. di Ematologia - Hematology Research Unit
The U.O. di Ematologia (Hematology Unit) is a specialized medical research center dedicated to advancing the understanding and treatment of complex hematological disorders. The center demonstrates particular expertise in investigating rare and challenging plasma cell dyscrasias, with a strong focus on Light Chain (AL) Amyloidosis, a severe systemic disorder characterized by the abnormal deposition of misfolded immunoglobulin light chains in vital organs.
- Phase 3 clinical trials in AL amyloidosis utilizing novel biologic therapies
- Advanced treatment strategies for high-risk Mayo Stage IV AL amyloidosis patients
- Investigation of combination therapies integrating innovative agents with standard of care protocols
The research unit's commitment to addressing the most critical cases is evident in its participation in multicenter, international studies targeting Mayo Stage IV subjects, representing the most advanced and life-threatening form of the disease. Through rigorous double-blind, placebo-controlled trials and extended open-label phases, the center contributes valuable data on both efficacy outcomes, including all-cause mortality, and long-term safety profiles of emerging therapeutic agents. This comprehensive approach positions the unit at the forefront of developing life-saving interventions for patients with limited treatment options.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Other Trials in U.O. di Ematologia
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Birtamimab with Standard Care versus Placebo in Mayo Stage IV Light Chain Amyloidosis: A Phase 3 Randomized, Double-Blind Study | Prothena Biosciences Limited | Phase III | Not Recruiting | Oct 2021 | May 2025 |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Birtamimab | 1 | Unknown | 2021-10-13 | 2021-10-13 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.